[Oncolytic enteroviruses]
- PMID: 23156670
[Oncolytic enteroviruses]
Abstract
Increasing information concerning molecular biology of viruses and virus-cell interactions makes it possible to use viruses as a tool in effort to treat cancer diseases. As a rule, tumor cells are highly sensitive to viruses that may be used in cancer therapy. Therewith, applications of viral oncolysis in treatment of cancer diseases assume maximum possible safety of used viruses for patient and environment. Human enteroviruses are one of the most convenient sources to generate oncolytic viruses. Many of enteroviruses are non-pathogenic for humans or cause mild disease. Progress in genetic engineering permits to develop attenuated enterovirus variants with high safety and selectivity. This review focuses on the main members of Enterovirus genus, such as Coxsackieviruses, and vaccine strains as promising source for development of oncolytic agents, applicable for cancer therapy. It reviews data concerning recently developed and tested oncolytic variants of enteroviruses and discusses perspectives of their application in cancer therapy and problems, concerning their improvement and practical use.
Similar articles
-
Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.Arch Immunol Ther Exp (Warsz). 2008 Dec;56 Suppl 1:3s-59s. doi: 10.1007/s00005-008-0047-9. Epub 2008 Dec 23. Arch Immunol Ther Exp (Warsz). 2008. PMID: 19104757 Review.
-
Vesicular stomatitis virus: re-inventing the bullet.Trends Mol Med. 2004 May;10(5):210-6. doi: 10.1016/j.molmed.2004.03.003. Trends Mol Med. 2004. PMID: 15121047 Review.
-
Potent oncolytic activity of human enteroviruses against human prostate cancer.Prostate. 2008 May 1;68(6):577-87. doi: 10.1002/pros.20741. Prostate. 2008. PMID: 18288643
-
[Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives].Mol Biol (Mosk). 2012 Jul-Aug;46(4):556-69. Mol Biol (Mosk). 2012. PMID: 23113343 Review. Russian.
-
Combining oncolytic virotherapy and tumour vaccination.Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):143-8. doi: 10.1016/j.cytogfr.2010.02.009. Epub 2010 Mar 11. Cytokine Growth Factor Rev. 2010. PMID: 20226716 Review.
Cited by
-
Hexokinase 2 controls cellular stress response through localization of an RNA-binding protein.Cell Death Dis. 2015 Aug 6;6(8):e1837. doi: 10.1038/cddis.2015.209. Cell Death Dis. 2015. PMID: 26247723 Free PMC article.
-
Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.Melanoma Res. 2015 Oct;25(5):421-6. doi: 10.1097/CMR.0000000000000180. Melanoma Res. 2015. PMID: 26193376 Free PMC article.
-
Receptors and Host Factors for Enterovirus Infection: Implications for Cancer Therapy.Cancers (Basel). 2024 Sep 12;16(18):3139. doi: 10.3390/cancers16183139. Cancers (Basel). 2024. PMID: 39335111 Free PMC article. Review.
-
Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future.Curr Pharm Biotechnol. 2023;24(2):266-278. doi: 10.2174/1389201023666220516121813. Curr Pharm Biotechnol. 2023. PMID: 35578840 Review.
-
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.Mol Ther Oncolytics. 2015;2:15011-. doi: 10.1038/mto.2015.11. Epub 2015 Jul 22. Mol Ther Oncolytics. 2015. PMID: 26640816 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials